Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
A bill implementing the provisions of the EU-Canada CETA trade deal is expected to be approved soon, bringing a new Certificate of Supplementary Protection together with an export manufacturing waiver, and some changes to the patent litigation system.
A new package of measures from the European Commission will introduce an SPC export manufacturing waiver to help improve the competitiveness of Europe’s generics and biosimilars industry, while originator companies should benefit from steps to smooth out the rules on the “Bolar” research exemption and implement an EU-wide SPC.
Malta has joined the ever-growing number of countries wanting to host the European Medicines Agency when it relocates from the UK post-Brexit. The European Commission has said new “technical issues” have been raised that will need to be addressed, and industry bodies have outlined the criteria they say need to be met by the future host country.
An amendment to the Medicines Act designed to limit distributors’ ability to parallel export medicines to higher priced EU markets has been signed, but some lawyers argue it might not be fit for purpose.
Germany, one of three countries whose signature is vital if the new Unified Patent Court is to get up and running, has taken another step towards ratification of the UPC agreement, while the Spanish parliament has approved a motion urging the government to drop its opposition to Spain’s becoming part of the new system.
As the Dutch elections draw near, the civil society body Health Action International has launched a campaign calling on a future government to tackle what it calls “soaring” drug prices. The move follows the adoption of a European Parliament Resolution demanding a better balance between public health imperatives and industry interests.